IFOND research | LHON treatment prospects | Mitochondrial Genome Editing | COVID-19 and LHON | LHON talks | Pay it forward | Mitochondrial Regulation | Avoid BAK eye drop preservative, etc. | We experiment with cigarette smoke so you need not. | Viral vector trials | EPI-743 LHON trials | Idebenone LHON trialsDigests: NEI News | Mitochondrial Disease News LHON | ARVO Journals LHON | PubMed LHON | Europe PMC LHON | MRC-MBU features
A randomized placebo controlled study published in the journal Brain showed idebenone to be an effective treatment for LHON. Idebenone is a synthetic benzoquinone, co-enzyme Q10 like substance, potent antioxidant and inhibitor of lipid peroxidation, which also interacts with the mitochondrial electron transport chain and facilitates mitochondrial electron flux through by-passing complex I. It was shown in the study to be well tolerated and have modest effectiveness in about half of LHON patients treated. The result confirms retrospective treatment data now published. People treated early in onset and for prolonged periods were likely to benefit most. This has been confirmed in real world clinical experience.
Use of Idebenone for the Treatment of Leber’s Hereditary Optic Neuropathy: Review of the Evidence Claudia B. Catarino MD, PhD, Thomas Klopstock, MD. Journal of Inborn Errors of Metabolism and Screening. Sage Journals. First Published September 18, 2017 Review Article. https://journals.sagepub.com/doi/full/10.1177/2326409817731112
Catarino, Claudia B. MD, PhD; von Livonius, Bettina MD; Priglinger, Claudia MD; Banik, Rudrani MD; Matloob, Selma MBChB, MRCOphth; Tamhankar, Madhura A. MD; Castillo, Lorena MD; Friedburg, Christoph MD, FEBO; Halfpenny, Christopher A. MBBS, PhD; Lincoln, John A. MD, PhD; Traber, Ghislaine L. MD; Acaroglu, Gölge MD; Black, Graeme C. M. DPhil, FRCOphth; Doncel, Carlos MD; Fraser, Clare L. MBBS, MMed; Jakubaszko, Joanna MD, PhD; Landau, Klara MD, FEBO; Langenegger, Stefan J. MD, FEBO; Muñoz-Negrete, Francisco J. MD, PhD; Newman, Nancy J. MD; Poulton, Joanna DM, MRCPCH; Scoppettuolo, Elisabetta MBBS, FRCOphth; Subramanian, Prem MD, PhD; Toosy, Ahmed T. MBBS, FRCP; Vidal, Mariona MD; Vincent, Andrea L. MBChB, MD; Votruba, Marcela BM BCh, FRCOphth; Zarowski, Marcin MD, PhD; Zermansky, Adam MBChB, FRCP; Lob, Felice MD; Rudolph, Günther MD; Mikazans, Oskars MA; Silva, Magda; Llòria, Xavier MD; Metz, Günther PhD; Klopstock, Thomas MD Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy, Journal of Neuro-Ophthalmology: September 22, 2020 - Volume Publish Ahead of Print - Issue - doi: 10.1097/WNO.0000000000001023 https://doi.org/10.1097/WNO.0000000000001023
The International Foundation for
Optic Nerve Disease
P. O. Box 777, Cornwall NY 12518, USA.
Web site: http://www.ifond.org/
IFOND is registered service mark of
The International Foundation for Optic Nerve Disease, est. October 1995.
Copyright 1999-2020, International Foundation for Optic Nerve Disease.
The information contained on this website should not be considered medical guidance or professional advice. IFOND is not responsible for errors or omissions in information provided on this site or actions resulting from its use. IFOND does not publish all information from all available sources on optic nerve disease. IFOND is not responsible for the validity of the studies or reviews nor is it an advocate of studies or reviews mentioned on or linked from the IFOND web site. IFOND does not endorse or recommend participation in any particular clinical trial or treatment protocol which may be mentioned on this site. Direct any questions concerning your personal health to your appropriate health care professional.